Introduction
The Society for Hematopathology and the European Association of Hematopathologists have undertaken as a joint project the development of a classification of hematological neoplasms for the World Health Organization (WHO). A steering committee composed of members of both societies has been formed, and 10 committees have been assigned the task of arriving at a consensus list of myeloid, lymphoid, and histiocytic neoplasms, with descriptions and criteria for diagnosis. A new classification for lymphoid neoplasms was recently proposed [1] , and the goals of the WHO project are to update and revise that classification, with input from additional experts in order to broaden the consensus, and to extend the principles of disease definition and consensus-building to the myeloid and histiocytic neoplasms. Over 50 pathologists from around the world have been involved in the project since 1995. Proponents of all major lymphoma and leukemia classifications have agreed that if a reasonable consensus emerges from this effort, they will accept the WHO as the standard classification of hematological malignancies. The final classification will be published under the auspices of the WHO [2] .
The proposed WHO Classification of hematological malignancies stratifies these neoplasms primarily according to lineage: myeloid neoplasms, lymphoid neoplasms, mast cell disorders, and histiocytic neoplasms (Tables  1-15) . Within each category, distinct diseases are defined Acute biphenotypic leukemias " Only major disease categories are listed: subtypes and variants will be discussed in detail in the text. b Acute lymphoid leukemias are included under lymphoid neoplasms and in Table 6 .
according to a combination of morphology, immunophenotype, genetic features, and clinical syndromes. The relative importance of each of these criteria differs among the neoplasms, and there is no one gold standard for classification of all hematologic malignancies. The Table 2 . Proposed WHO Classification of lymphoid neoplasms. goal is to define disease entities that can be recognized by pathologists, and that have clinical relevance. In order to ensure that the proposed classification will be of maximal use to oncologists, the Steering Committee invited expert hematologists and oncologists to form a Clinical Advisory Committee, with American and European co-chairs. The charge to the committee was to review the proposed classification and advise the pathologists on its clinical utility. Over 40 hematologists and oncologists from around the world agreed to Table 4 Mast cell diseases.
• Cutaneous mastocytosis • Systemic mast cell disease ( + / -skin involvement) • Systemic mast cell disease with associated hematologic disorder (+/-skin involvement) • Mast cell leukemia/sarcoma participate. The proposed classification was circulated, and all participants were invited to submit topics and questions for discussion. A meeting was held in November, 1997, at Airlie House, Virginia, to which the Clinical Advisory Committee and all pathologists involved in the WHO committees, as well as the Executive Committees of the two hematopathology societies, were invited.
The meeting was organized around a series of questions, developed from those submitted by Clinical Advisory Committee members as well as those posed by the pathologists. Only issues that were controversial were discussed; diseases for which there were no new questions or data were accepted as previously defined. Only lymphoid and myeloid neoplasms were discussed at this meeting; histiocytic and mast cell tumors were not considered. Participants were invited to present data relevant to each question, and open discussion followed. At the end of each session, the clinicians present were asked to arrive at a consensus regarding each question (as well as on other issues raised at the meeting); if necessary a show of hands was taken as a vote. Following the meeting, a poll of the participants, as well as several additional meetings of the pathology Steering Committee and the co-chairs of the Clinical Advisory Committee were held to resolve residual questions.
Myeloid neoplasms
Although there have been many advances in the understanding of genetic factors in the biology of the myeloid Table 5 . Histiocytic and dendritic-cell neoplasms.
Alacrophage/histiocylic neoplasm • Histiocytic sarcoma

Dendritic-cell neoplasms
Langerhans cell histiocytosis Langerhans cell sarcoma Interdigitating dendritic cell sarcoma/tumor Follicular dendritic cell sarcoma/tumor Dendritic cell sarcoma, not otherwise specified (NOS) neoplasms, particularly the acute leukemias, the classification of these disorders has not been recently updated. Thus, the discussion of these disorders generated considerable controversy, and several subsequent meetings of pathologists and the clinical co-chairs occurred, during which a consensus on the classification emerged. The following summary includes both issues raised at the Clinical Advisory Committee meeting and resolutions achieved subsequently.
In the French-American-British (FAB) Classification, three main categories of myeloid neoplasms are recognized: acute myeloid leukemias, myelodysplastic syndromes, and myeloproliferative disorders [3] . The blast count, lineage commitment and level of differentiation of the neoplastic cells are the major determinants of the categories recognized, using morphologic, cytochemical, and immunophenotypic features. Recently, genetic features (cytogenetic and molecular genetic) as well as other features such as prior therapy and a history of myelodysplasia have been shown to have a significant impact on the clinical behavior of these disorders, and these features do not always correlate perfectly with the FAB categories. Thus, a major focus of debate was how to integrate genetic and clinical features with morphology, cytochemistry, and immunophenotype into a classification that can be used by pathologists and will have clinical relevance. A key issue, as with the lymphoid neoplasms, is to discriminate between disease entities and prognostic factors. Some genetic abnormalities appear to define distinct diseases, while others are prognostic factors within a given disease. Another issue debated was whether all diseases fit into one of the three major categories, or whether additional broad categories are needed.
After discussion, it appeared that a paradigm similar to that adopted for the R.E.A.L. Classification of lymphoid neoplasms can at least tentatively apply to the myeloid disorders; namely, that a combination of morphology, immunophenotype, genetic features and clinical features is used to define distinct disease entities. The technology of genetic analysis is moving rapidly, and it is likely that advances in this field will necessitate revisions to any current classification in the near future. The pathologists propose four major groups of myeloid diseases: myeloproliferative diseases (MPD), myelodysplastic/myeloproliferative diseases (MD/MPD), myelodysplastic syndromes (MDS), and acute myeloid leuke-mias (AML). Within the category of AML, 4 main groups are recognized: 1) AML with recurrent cytogenetic translocations; 2) AML with myelodysplasia-related features; 3) therapy-related AML and MDS; 4) AML not otherwise categorized.
Myeloproliferative diseases
Myeloproliferative diseases (MPD) are clonal stem cell disorders that are characterized by 'effective' hematopoiesis, resulting in elevated peripheral blood levels of one or more cell lines and hepatosplenomegaly; there is marrow hypercellularity with maturation and without dysplasia. Among the myeloproliferative disorders, the prototype is Philadelphia chromosome (Phl)+ [BCR/ ABL+] chronic myelogenous leukemia (CML). The other accepted entities are polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Controversies within this group include the definitions and classification of juvenile myelomonocytic leukemia (also known as juvenile chronic myeloid leukemia and juvenile chronic myelomonocytic leukemia), chronic myelomonocytic leukemia, and atypical CML.
Should juvenile myelomonocytic leukemia be a separate category? Should it be classified as MDS or MPD?
The Clinical Advisory Committee accepted the conclusions of the international study group for pediatric MDS that this is a separate disorder, distinct from adult chronic myeloid or myelomonocytic leukemias. It has been proposed that the name 'juvenile myelomonocytic leukemia (JMML)' be adopted. The committee favored including it in the myeloproliferative disorders; however, the pathologists recommend that a separate category be formed to include this and other disorders that combine features of myeloproliferative and myelodysplastic syndromes.
Should chronic myelomonocytic leukemia (CMML) be divided into MDS and MPD types? CMML has long been recognized as a disorder that has features of both myelodysplastic and myeloproliferative syndromes. Nearly half the patients present with low or normal neutrophil counts, multilineage marrow dysplasia, no organomegaly, and bone marrow morphology that resembles refractory anemia with excess blasts (RAEB) but with monocytosis. Other patients have marked neutrophilia, monocytosis, and splenomegaly. It has been debated whether this is really two diseases -one a MDS and the other a MPD. However, studies to date have shown no differences in cytogenetic abnormalities, oncogene mutations, in vitro colony growth patterns, or clinical outcome between the two types of CMML. It was the consensus of the meeting that this is one disease. The committee concluded that it fits better in the MPD than in the MDS category, but after subsequent discussions, the pathologists recommend that it be included in a separate category, with JMML. of disorders with both myeloproliferative and myelodysplastic features.
What should be the nomenclature and category for atypical CML? This disease was first recognized as a disease involving predominantly the neutrophil series, that lacked Phi or BCR/ABL translocation, which has dysplastic as well as proliferative features, often with multilineage dysplasia. The prognosis is significantly worse that that of Phl+ CML. It is clear that it is clinically, genetically, and morphologically distinct from Phl + CML, and the name, atypical CML (aCML) is therefore suboptimal, implying both a relationship to Phi + CML and a chronic process. The committee was unable to agree on another name, and felt that the term aCML could be retained, provided a clear definition of the disease was provided in order to prevent confusion. The pathologists recommend placing this disease with JMML and CMML in a category of 'Myelodysplastic/myeloproliferative' diseases.
Should there be a separate category for cases that are neither MDS nor MPD? For reasons mentioned above, the pathologists recommend a fourth category of myeloid neoplasms, to contain those cases that are inherently proliferative but show dysplastic features, including JMML, CMML, and aCML. It was the opinion of the clinicians present that such a category was not desirable, and that these diseases could be placed in the MPD category. However the pathologists contended that these disorders have many features in common, including abnormalities of both granulocytic and monocytic lines and a relatively aggressive course, that distinguish them from both the MDS and MPD categories and argue for placing them together. 
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Whalblast count should define A ML? The FAB standard has been 30% blasts. However, recent studies have indicated that patients with 20%-30% blasts (classified as refractory anemia with excess blasts in transformation, RAEB-T) have a prognosis similar to that of patients with > 30% blasts. Thus, there was a consensus that the blast count for the diagnosis of AML should be 20% and the category of RAEB-T should be dropped. The specific morphologic features of these disorders will be described in the classification, and these entities will be excluded from the FAB categories used for cases lacking these abnormalities. In addition, cases with these specific cytogenetic abnormalities with low blast counts, which might in the past have been diagnosed as MDS, will now be classified as AML.
Should multilineage dysplasia, prior MDS, and/or prior theray, be included in classification of AML?
Severe multilineage dysplasia, defined as the presence of dysplastic features in the cells of two or more lines, has been shown to be associated with poor outcome in AML. Similarly, AML arising in patients with a history of MDS also have a poor prognosis. Therapy-related leukemias secondary to alkylating agent therapy are clearly different from many de novo acute leukemias; they are associated with characteristic cytogenetic abnormalities (3q--5, 5q--7, 7q-+8, +9, l l q -12p--18, -19, 20q-, +21, t(l;7), t(2;ll), complex karyotypes) and a worse prognosis, and often show multilineage dysplasia or are preceded by a hypoproliferative state with multilineage dysplasia, resembling MDS. Similar cytogenetic abnormalities are often seen in MDS not associated with prior therapy, as well as in de novo acute leukemias, particularly in the elderly. It has been suggested that all of these disorders reflect similar genetic damage, which may be either environmental or iatrogenic. There was a consensus that the presence of multilineage dysplasia at the time of the diagnosis of acute leukemia, a history of myelodysplasia , or prior alkylating agent therapy were all adverse prognostic factors, which may reflect a common pathogenesis. The committee concluded that multilineage dysplasia, a history of MDS, and a history of alkylating agent therapy should be included in the classification of AML.
The specific cytogenetic abnormalities common to both MDS, alkylating agent-related AML, and poorprognosis AML (3q-, -5 , 5q-, -7, 7q-, +8, +9, l l q12p--18, -19, 20q-+21, t(l;7), t(2;Il), complex karyotypes), likely reflect a common pathogenesis of these lesions, distinct from that of other de novo AML. However, there was no consensus on the role of these abnormalities in defining disease entities within the classification. Our understanding of this issue will likely improve in the near future, necessitating a change in the major groupings. However, for the present, cytogenetic abnormalities indicative of poor prognosis should be recognized as prognostic factors within each category of AML.
Therapy with topoisomerase II inhibitors (epipodophyllotoxins and adriamycin) is also associated with secondary leukemias, which are often myeloid but may be lymphoid. These typically show cytogenetic abnormalities associated with de novo AML -most commonly translocations involving Ilq23 (MLL), but also occasionally t(8;21), inv(16) or t(15;17). These cases should also be recognized in the classification as distinct from alkylating-agent related secondary leukemias.
Should refractory cytopenia with multilineage dysplasia be a separate category? Myelodysplastic syndromes are clonal stem cell disorders characterized by ineffective hematopoiesis, resulting clinically in peripheral blood cytopenias; the marrow is variably hypercellular, and patients show poor responses to chemotherapy, with an increased risk of progression to acute leukemia. The terms, refractory anemia (RA) and refractory anemia with ring sideroblasts (RARS) were defined in the FAB classification as having dysplasia largely restricted to the erythroid line. Recent studies have shown that cases of MDS with < 5% blasts but with significant dysplasia involving granulocytic and megakaryocytic lines have a worse prognosis and are more likely to die of marrow failure or progress to acute leukemia (similar to RAEB) than those lacking these features. Thus, the committee agreed that a separate category is needed for these cases. Multilineage dysplasia is defined as the presence of dysplastic features in the cells of 2 or more lines. Refractory anemia (with or without ring sideroblasts) will continue to be defined as a disorder involving the erythroid line only. MDS will exclude cases of low blast-count leukemias that show one of the AML type cytogenetic abnormalities -t(8;21), inv(16), or t(15;17). Because of the distinctive morphologic and clinical features of the 5q-syndrome, it was agreed by the pathologists that this should be a separate category within MDS. 
Lymphoid neoplasms
The proposed WHO Classification of lymphoid neoplasms adopts the Revised European-American Classification of Lymphoid Neoplasms (R.E.A.L.), proposed by the International Lymphoma Study Group. This classification is based on the premise that a classification should attempt to define distinct disease entities, using all available information, including morphology, immunophenotype, genetic features, and clinical features. There is no one 'gold standard', and the importance of various criteria for both definition and diagnosis differ among different diseases. Based on experience with using this classification for several years and on input from the committees, several changes were proposed for the WHO version. These include some changes in nomenclature, splitting some categories that were believed to be heterogeneous, and adopting some 'provisional' entities as 'real'. The proposed classification recognizes B-cell neoplasms, T/NK-cell neoplasms, and Hodgkin's disease. TheT-and B-cell neoplasms are stratified into precursor, or lymphoblastic neoplasms (acute lymphoblastic leukemia and lymphoblastic lymphoma) and mature ('peripheral') B and T-cell neoplasms. The mature B and T-cell neoplasms are informally grouped according to their major clinical presentations: predominantly disseminated/leukemic, primary extranodal, and predominantly nodal diseases. The pathologists sought input from the clinicians on these changes, and also on some issues that remain controversial or problematic, such as grading of follicular lymphoma, how to define 'Burkitt-like' lymphoma, subclassification of large B-cell lymphoma and mature T-cell lymphomas, and the desirability of clinical groupings of the non-Hodgkin's lymphomas.
Precursor neoplasms
Should the FAB terms (LI,2,3) be retained? There was a consensus that these terms are no longer relevant, since LI and L2 morphology do not predict immunophenotype, genetic abnormalities, or clinical behavior. L3 is generally equivalent to Burkitt's lymphoma in leukemic phase, and should be diagnosed as such (Table 6) .
Are lymphoblastic leukemias and lymphoblastic lymphomas a single disease with different presentations?
There was a consensus that the precursor neoplasms presenting as solid tumors and those presenting with marrow and blood involvement are biologically the same disease, but with different clinical presentations The presence of bone marrow and peripheral blood involvement are principally prognostic factors/staging issues, not classification issues, although the biological basis for the different clinical presentations is not fully understood. jgists and those presenting with tissue involvementlphomas -by oncologists), there was a consensus t they are biologically the same diseases (Table 7) .
licular lymphoma mid the nomenclature be changed to follicular lym>ma?
The WHO committee proposed to change the nenclature from 'follicle center lymphoma' to 'folilar lymphoma'. The Clinical Advisory Committee :rwhelmingly approved this proposal. For the rare e of purely diffuse lymphoma that appears to be of icle center origin (predominance of centrocytes, rare troblasts, BCL-2 rearranged), the term, follicle center iphoma, diffuse, will be retained as a separate catey. This diagnosis should only be made if both small I large cells are B cells, and preferably with demonstrai of some indicator of follicle center derivation, such 3CL-2 rearrangement or CD10 expression (Table 8) . 
Marginal zone lymphomas Should the term, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MALT-type lymphoma be applied only to a lymphoma composed mostly of small cells? What should be the terminology for large-cell lymphoma in a MALT site?
The term, 'high-grade MALT lymphoma', which is used by some pathologists to denote either transformation of a low-grade MALT lymphoma or any large B-cell lymphoma in a MALT site, is confusing to clinicians, who have come to regard the term, MALT lymphoma, to be synonymous with a lesion that may respond to antibiotic therapy for eradication of Helicobacter pylori. Since experience indicates that patients with a component of large-cell lymphoma do not respond to antibiotic therapy, the oncologists were concerned that use of this term may result in cases of extranodal large-cell lymphoma being undertreated. Furthermore, recent data show that the types of cytogenetic abnormalities seen in low-grade MALT lymphomas, differ from those seen in primary large-cell lymphoma of the stomach, raising the question of whether these primary lymphomas are really related to low-grade MALT lymphomas. Therefore, the oncologists preferred that the term, MALT lymphoma, be used only for the low-grade lymphoma originally described as 'low-grade B-cell lymphoma of MALT'.
Areas of large-cell lymphoma, if present, should be separately diagnosed as 'diffuse large B-cell lymphoma'. Primary large-cell lymphomas of MALT sites should be diagnosed as 'diffuse large B-cell lymphoma', not as 'high grade MALT lymphoma'. 
Should marginal zone/MALT lymphoma be graded by the proportion of large cells?
Are cases of B-CLL with plasmacytoid differentiation (lymphoplasmacytoid immunocytoma in the Kiel Classification) a different disease from typical CLL?
Data from several groups using the Kiel Classification suggest that plasmacytoid differentiation may be an adverse prognostic factor in B-CLL; the committee felt that the available data do not support calling it a different disease, and that further study was needed to determine whether plasmacytoid differentiation was an adverse prognostic factor in CLL. Therefore, recognition of this feature is not required for diagnosis for clinical purposes, but criteria for diagnosing plasmacytoid differentiation should be agreed on if possible for future studies (Table 7) . Nonetheless, neither reliable p£ criteria for subclassification n that can be recommended for cl able at this time. For these rea: that these categories should r time. However, there was agrei gists should develop criteria f that these categories can be t studies (Table 9) .
Should 'Burkitt-like' or 'non-Bi subtype of DLBCL, a subtype Oj a distinct category? What shot
The pathologists proposed to c phoma as a subtype of large B-c there was a clear consensus am this would be a mistake. There ai ing that in children, cases class non-Burkitt) behave identically and would be undertreated if lymphoma. In adults, the biolo Burkitt-like is less clear, but thi geneity of the diagnostic criter NHL study, Burkitt-like was a nc with only about 50% agreement the major areas of overlap wer lymphoma. The oncologists urj Burkitt-like lymphoma be res should be treated 'like Burkitt very high-grade tumors. The co Burkitt-like lymphoma should logic variant of Burkitt's lymph fication. The term 'atypical Bi proposed for this variant; howi mittee subsequently decided th was preferable, since the relationship to Burkitt's lymphoma is not known in all cases. Thus, the category of Burkitt's lymphoma will include classic Burkitt's lymphoma and a variant -Burkitt-like lymphoma. In addition, three sub-categories -endemic, non-endemic, and immunodeficiency-associated -were proposed to reflect the major clinical and genetic subtypes of this disease (Table 10 ). At present, there are no readily available immunophenotypic criteria that can be used in this differential diagnosis. However, participants observed that probably both the morphology and the biology of Burkitt's lymphoma are defined by the presence of c-MYC rearrangement and overexpression, which results in all cells being perpetually in cycle. The gold standard for the diagnosis of Burkitt's lymphoma should be the presence of the t(8;14)(q24;q32) and its variants or cMYC rearrangement. Cytogenetic analysis is recommended in all leukemic cases. If cytogenetic or Southern blot analysis is not available in solid tumors, it seems likely that the most reasonable surrogate for cMYC rearrangement is proliferation fraction. Therefore, it was suggested that cases in which cytogenetic analysis is not available should not be diagnosed as Burkitt's lymphoma or Burkitt-like lymphoma without a Ki-67 fraction close to 100%. Thus, the definition of Burkitt-like lymphoma is a lymphoma that morphologically resembles Burkitt's lymphoma, but has more pleomorphism or large cells than classical Burkitt's lymphoma, and has a proliferation fraction of > 99%.
Do we need separate categories for clinical subtypes of DLBCL?
There are multiple distinct clinical presentations of DLBCL, several of which have unique clinical behavior these include mediastinal/thymic large B-cell lymphoma, primary CNS lymphoma, and primary effusion lymphoma. Of particular concern to pathologists is the category of cutaneous B-cell lymphoma; most of which have a very indolent clinical course. One category -marginal zone/MALT lymphoma -is easily recognized by pathologists as a low-grade iymphoma. However, the other major category, called 'cutaneous follicle center lymphoma' in the recently-proposed EORTC Classification, has a range of morphology, from a clearly low-grade lesion resembling nodal follicular lymphoma to a diffuse proliferation with numerous large cells that may be called DLBCL by pathologists. This type of lymphoma. which is typically localized to the head and trunk, responds well to local therapy (excision or radiation), and typically does not disseminate to lymph nodes, comprised 70% of cutaneous B-cell lymphomas in the EORTC study. There is concern that if its distinctive histologic and clinical features are not recognized by both pathologists and oncologists, these patients will be over-treated with aggressive chemotherapy (Table 8) .
The consensus of the committee was that separate classifications of lymphomas at specific extranodal sites were not needed for clinical purposes. However, the site of involvement should be clearly stated in the pathology report, and oncologists are obliged to understand the distinctive clinical features of lymphomas at various sites. Distinct entities such as primary mediastinal (thymic) B-cell lymphoma, primary effusion lymphoma, and intravascular lymphoma will be described in the text as subtypes of DLBCL. The committee recommended that the distinctive clinical features of B-cell lymphomas in the skin be indicated in the text describing each lymphoma subtype. Hodgkin's disease is more aggressive and always EBV+ in HIV+ patients. The recently described primary effusion lymphoma, which was initially thought to be unique to HIV+ patients, has been reported in HIV-patients as well. T-cell lymphomas in HIV+ patients also do not appear to be distinctive. A recently described plasmablastic lymphoma is distinctive, and its relationship to myeloma remains to be determined. The polymorphic post-transplant lymphoproliferative disorders (PTLD) appear to be a unique form of lymphoproliferation that do not occur in immunologically normal individuals. It was suggested that EBNA-2 expression in these lesions indicates that the proliferation is EBV driven and may respond to reduced immunosuppression.
In summary, the committee suggested that a separate classification was not needed for immunodeficiencyassociated lymphomas, but that the specific types of lymphomas that occur in immunodeficiency states and their distinctive features in these conditions should be indicated both in the text and in a table. In addition, the pathologists felt that a separate classification of PTLD would be useful, because of their distinctive biological and clinical features ( 
Mature (peripheral) T-cell neoplasms
Are clinical syndromes integral to the definition of T/NK-cell neoplasms?
Many distinct T and/or NK-cell diseases have a range of cytologic composition (small to large to anaplastic). Immunophenotypic variation exists within disease entities, and many antigens are shared by different diseases. Specific cytogenetic features are not defined for most entities, and even T-cell receptor types (a (3 vs. yb) or T vs. NK lineage are not sufficient to define distinct disease entities. To a greater extent than is appreciated for B-cell neoplasms, it appears that clinical syndromes, and particularly location (nodal vs. extranodal and specific extranodal sites) are important in determining the biological behavior of the disease. The committee agreed that clinical syndromes appear to be integral to the definition of Tand NK-cell neoplasms.
Should peripheral T-cell lymphoma, unspecified, be subclassified (according to the Kiel Classification) for clinical p urposes ?
Based on the available data, there appears to be no immediate justification for or clear criteria for recognizing cytologic subtypes within this broad category. However, given the marked differences in clinical behavior between primary extranodal T/NK-cell lymphomas and primary nodal lymphomas, it is likely to be clinically relevant to subdivide the 'unspecified'category into nodal and extranodal types. Both pathologists and oncologists will need to continue to address this area in further studies. There is evidence that most cases of ALCL of T-cell type presenting with disease localized to the skin are a different disease from systemic ALCL: the clinical course is indolent, they lack the t(2;5)(p23;q35) and are ALK protein negative, and appear to form a spectrum with lymphomatoid papulosis. Although some members of the committee felt that the clinical course was not predictably indolent, there was general agreement that at least for the purposes of further study, cutaneous and systemic ALCL should be considered distinct categories. There was significant concern, however, about the proposed term, 'primary CD30+ cuta- neous lymphoproliferative disorder' -a term that includes lymphomatoid papulosis, cutaneous ALCL, and CD30+ cutaneous T-cell lymphomas that do not have typical 'anaplastic' morphology. Oncologists felt that including lymphomatoid papulosis in a classification of lymphomas would imply to patients and insurers that this is a malignancy, whereas it typically has a benign clinical course.
In conclusion, the committee agreed that the entity, primary cutaneous ALCL, should be included in the list of neoplasms, and a discussion of 'CD30+ cutaneous lymphoproliferative diseases' should be included in the text with a discussion of lymphomatoid papulosis and borderline lesions. Because of the difficulty in predicting by morphology alone which disease the patient has, pathologists will often be forced to use the term 'CD30+ cutaneous lymphoproliferative disease' on the pathology reports, with the understanding that clinical criteria must be added to determine whether the patient has a locally progressive disease that requires treatment (ALCL), or a relapsing condition that needs no treatment (lymphomatoid papulosis).
What is the gold standard for defining ALCL? Given the recent availability of an antibody to the ALK protein, which is highly associated with the t(2;5)(p23;q35), the question was raised whether this can be used as the defining criterion for ALCL. Clinically, cases with the t(2;5) and/or ALK positivity appear to represent a homogeneous group with a relatively good prognosis. However, others observed that experience with ALK antibodies is limited and they are only now becoming commercially available. In addition, there are cases with typical morphology and immunophenotype that are ALK or t(2;5) negative. The committee concluded that a single 'gold standard' for the diagnosis of ALCL does not exist; the diagnosis requires both morphology and immunophenotype, and at least at present, restricting the diagnosis to ALK+ cases does not appear to be justified. It was suggested that ALK staining be done in all cases to the extent possible, and that cases be designated as ALCL. ALK+ or ALK-. at least for research purposes. In addition, pathologists need to be aware of the rather broad morphologic spectrum of ALCL. Because it is now clear that Hodgkin's disease is a clonal proliferation of (in most cases) B cells, and therefore qualifies as a lymphoma, the pathologists proposed that the name be changed to Hodgkin's lymphoma. Opinion of the committee was divided on this score, with some feeling that patients become confused as to whether they have a lymphoma or not, when the term 'disease' is used, and others standing on tradition and resisting unnecessary change. No consensus was reached.
Lymphocyte-rich classical HD (LRCHD): Is it a 'real' subtype?
Very little clinical data exist on this subtype, proposed as 'provisional' in the R.E.A.L. Classification. The com- 
Clinical groupings of B andT/NK-cell lymphomas
Are clinical groupings useful for clinical practice?
The committee concluded that grouping the B and T/NK-cell neoplasms into prognostic categories would serve no clear purpose and could hamper understanding of the specific features of some of the diseases. There are no groups of diseases that require identical treatment, and if treatment must be individualized to a specific disease, grouping serves no purpose and may be misleading. The entities listed in the classification are clearly defined and clinically relevant, and it is necessary for oncologists and pathologists dealing with these diseases to understand each of them.
Is a shorter list of diseases necessary for clinicians?
The committee also discussed whether a shorter list of common diseases should be prepared for clinical use.
There was a clear consensus that the complete list of neoplasms should have more common entities highlighted, to draw the attention of non-experts to the diseases they are likely to encounter in practice. Opinion was split on the need for a 'short list', and a poll taken after the meeting showed a majority of the oncologists favoring one comprehensive list with common entities highlighted 
Unclassifiable hematologic malignancies
Even with the advances in immunophenotyping and genetic analysis, some hematologic malignancies still defy classification. A case may be unclassifiable because of an inadequate tissue sample, because special studies are not available, because the tissue is poorly preserved, or because even with complete analysis it does not fit into one of the categories recognized in the classification. For each case, the reason for the inability to classify it should be stated in the Pathology report. Suggested categories and terminology for unclassifiable cases are listed in Table 16 .
Conclusions
The committee concluded that the approach to the classification of hematologic malignancies proposed by
